Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML

Bone Marrow Transplantation volume 44, pages 345–351 (2009)Cite this article

Abstract

We examined whether the use of G-CSF-primed unmanipulated bone marrow (pBM) permits successful transplantation in patients with adverse comorbid pretransplantation conditions. A total of 33 patients at variable risk of AML undergoing allogeneic SCT from an HLA-identical sibling participated. The patients suffered from a variety of treatment-related sequelae before SCT and many cases also featured the presence of major organ dysfunction. The median follow-up duration of patients who were among the overall survivors was 58 months (range, 11−125 months). The median number of CD34+ cells infused was 3.5 × 106 per kg (range, 0.8−15.6 × 106 per kg). The median number of days for recovery of ANC and platelet count without transfusion was 13 (range, 6−22) and 18 (range, 11−29) days, respectively. Four patients (12%) died due to nonrelapse causes and only one patient developed the same course of infectious complication as before SCT. No particular finding in the context of CMV infection or other post transplant complication was observed. The estimated 10-year overall survival rate was 68%. Our results suggest that the use of pBM allows successful engraftment without increasing complications in patients with various comorbidities before transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  2. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipient of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–1531.

    Article  CAS  PubMed  Google Scholar 

  3. Isola LM, Scigliano E, Skerrett D, Shank B, Ross V, Najfeld V et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997; 20: 1033–1037.

    Article  CAS  PubMed  Google Scholar 

  4. Isola L, Scigliano E, Fruchtman S . Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6: 428–433.

    Article  CAS  PubMed  Google Scholar 

  5. Serody JS, Spark SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434–440.

    Article  CAS  PubMed  Google Scholar 

  6. Morton J, Hutchins C, Durrant S . Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186–3191.

    Article  CAS  PubMed  Google Scholar 

  7. Elfenbein GJ, Sackstein R, Oblon DJ . Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No!. Blood Cells Mol Dis 2004; 32: 106–111.

    Article  CAS  PubMed  Google Scholar 

  8. Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125: 480–493.

    Article  PubMed  Google Scholar 

  9. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.

    CAS  PubMed  Google Scholar 

  10. Langer T, Beck JD, Gravou-Apostulatou C, Lang P, Handgretinger R, Greil J . Successful treatment of primary refractory acute myeloid leukemia with megadose stem cell transplantation, bone marrow boost and reduced intensity conditioning avoiding chronic graft vs. host disease and severe late toxicity. Pediatr Transplant 2003; 7: 494–496.

    Article  PubMed  Google Scholar 

  11. Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Xue M et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861–866.

    Article  PubMed  Google Scholar 

  12. Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-b-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen-a prospective, cooperative multicenter study. Semin Hematol 1996; 33 (Suppl 3): 24–29.

    CAS  PubMed  Google Scholar 

  13. Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC . Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients. Hematol Oncol 2007; 25: 76–83.

    Article  CAS  PubMed  Google Scholar 

  14. Kim HJ, Min WS, Eom KS, Cho BS, Kim SY, Bok JN et al. Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. Bone Marrow Transplant 2007; 40: 1069–1074.

    Article  PubMed  Google Scholar 

  15. Kim HJ, Min WS, Eom KS, Park SJ, Park YH, Kim DW et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2004; 34: 215–220.

    Article  CAS  PubMed  Google Scholar 

  16. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.

    CAS  PubMed  Google Scholar 

  17. Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS et al. CD34+ cell dose predicts relapse and survival after T-cell depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000; 108: 408–414.

    Article  CAS  PubMed  Google Scholar 

  18. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106/kg CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489–496.

    Article  CAS  PubMed  Google Scholar 

  19. Majolino I, Saglio G, Scime R, Serra A, Cavallaro AM, Fiandaca T et al. High incidence of chronic GvHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555–560.

    CAS  PubMed  Google Scholar 

  20. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  21. Frangoul H, Nemecek ER, Billheimer D, Pulsipher MA, Khan S, Woolfrey A et al. A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood 2007; 110: 4584–4587.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A05-0223-AA1018-06A2-00010A).

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    H-J Kim, W-S Min, B-S Cho, K-S Eom, S-Y Kim, Y-J Kim, S Lee, C-K Min, S-G Cho, J-W Lee & C-C Kim

Authors
  1. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W-S Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B-S Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K-S Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S-Y Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C-K Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S-G Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J-W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C-C Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W-S Min.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HJ., Min, WS., Cho, BS. et al. Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML. Bone Marrow Transplant 44, 345–351 (2009). https://doi.org/10.1038/bmt.2009.42

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.42

Keywords

Search

Advanced search

Quick links